Syndax Pharmaceuticals, Inc. — Income Charts
44 quarters of history · ending 2025-12-31 · SEC EDGAR
Revenue↑+794.9% +$61M
$69M
R&D↑+20.0% +$13M
$79M
Operating Income↑+35.9% +$32M
$-57M
EBITDA↑+35.9% +$32M
$-57M
Interest Expense
$0
Tax Provision
$433K
Net Income↑+27.8% +$23M
$-61M
Operating Margin↑+591.4pts
-125.2%
Net Margin↑+540.6pts
-132.4%